Faculty
Faculty Publications
Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [11 C]DASB PET study. | |
---|---|
Year of publication | 2018 |
Title of paper | Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [11 C]DASB PET study. |
Author | Lee J, Kim BH, Kim E, Howes OD, Cho KIK, Yoon YB, Kwon JS. |
Publication in journal | Human Psychopharmacology: Clinical and Experimental |
Status of publication | accepted |
Vol | 33(1) |
File | hup.2642.pdf (304.4K) 7회 다운로드 DATE : 2020-03-31 10:00:39 |
Link | https://onlinelibrary.wiley.com/doi/full/10.1002/hup.2642 273회 연결 |
OBJECTIVE:Early-onset obsessive-compulsive disorder (EOCD) and late-onset obsessive-compulsive disorder (LOCD) are distinct subtypes of obsessive-compulsive disorder (OCD). OCD patients are treated with serotonin reuptake inhibitors, but the difference in serotonin transporter (SERT) availability between medicated EOCD and LOCD is unexplored yet. METHODS:Six EOCD and 6 LOCD patients were enrolled. They underwent serial [11 C]DASB positron emission tomography scans during maintenance therapy with escitalopram, and their plasma concentration of escitalopram was measured simultaneously with the scan. Then, the drug-free binding potential of SERT was calculated by pharmacokinetic-pharmacodynamic modelling. RESULTS:In comparison with LOCD patients, SERT availability was significantly higher in the putamen of EOCD patients (U = 4, p = .026), but not in the caudate nucleus (U = 14, p = .589), thalamus (U = 16, p = .818), and dorsal raphe nucleus (U = 7, p = .093). Binding potential of putamen showed a negative correlation (r = -.580, p = .048) with age of onset of the disease, but not with the Yale-Brown Obsessive Compulsive Scale scores. CONCLUSIONS:These findings indicate that the earlier the age of onset of OCD, the less serotonergic pathology there is and that this difference remains even after long-term serotonin reuptake inhibitor treatment. Clinically, it might suggest that nonserotonergic treatments would be a better option for EOCD patients.
KEYWORDS:[11C]DASB PET; age of onset; escitalopram; obsessive-compulsive disorder; serotonin transporter |